No insider purchase over the last 90 days. The latest, by 정종철, was filed 04 Aug 2026.
SyntekaBio, Inc.: what insiders have been doing
SyntekaBio, Inc. belongs to the Health Care sector. Filings by its managers are published through DART (FSS). In the past year (31 October 2025 to 31 October 2026), 26 filings came from 5 insiders.
Both sides are active: 18 purchases worth €53k and 1 sale, from 4 insiders and 1 insider respectively. No amount is published for 18 filings, which the totals therefore leave out. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Biggest ticket of the year: €53k, bought by 정종선 and made public on 2 July 2026. The buyers include 2 board members, 2 chief executives and 1 major shareholder.
Across the 2,655 companies tracked on its exchange, the median is 7 filings; at 26 filings, this issuer sits above that mark. Looking back to 2021, when coverage begins, insiders filed 52 purchases and 9 sales.
The last purchase on record was published on 4 August 2026, which is 97 days ago. The median gap between a trade and its publication by DART (FSS) is 7 days. Until a filing is published, the market cannot know about the trade.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and UCB. Every figure here comes from the filings published by DART (FSS) and describes the past, not future prices; it is not investment advice.
Who traded when
BuySaleSince the insiders bought
- -34.3%Entry ₩1,573 · Close 30 Oct 2026 ₩1,034
- -36.2%Entry ₩1,620 · Close 30 Oct 2026 ₩1,034
- -67.1%Entry ₩3,145 · Close 30 Oct 2026 ₩1,034
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- 37,783 sharesShareKRXDART:20260804000089Canonical exit: 2 Nov 2026 (T+90)
- 15,139 sharesShareKRXDART:20260728000500Canonical exit: 27 Oct 2026 (T+90)
- Other0DART
- 16,764 sharesKRXDART:20260715000424Canonical exit: 13 Oct 2026 (T+90)
- 213,570 sharesKRXDART:20260706000452Canonical exit: 4 Oct 2026 (T+90)
- 60,000 sharesShareKRXDART:20260706000448Canonical exit: 4 Oct 2026 (T+90)
- 44,693 sharesShareKRXDART:20260703000255Canonical exit: 1 Oct 2026 (T+90)
- 60,000 shares@ ₩1,562.00100.0% of flowShareKRXDART:20260702000512Canonical exit: 23 Sept 2026 (T+90)
- 213,570 sharesKRXDART:20260702000496Canonical exit: 30 Sept 2026 (T+90)
- ●Executives0DART
- ●Executives0DART
- KRXDART:20260528001029
- 90,000 sharesKRXDART:20260518000389Canonical exit: 10 Aug 2026 (T+90)
- 90,000 sharesShareKRXDART:20260518000392Canonical exit: 16 Aug 2026 (T+90)
- 30,678 sharesShareKRXDART:20260407003064Canonical exit: 30 Jun 2026 (T+90)
- ●Executives0DART
- 0KRXDART:20260306000924
- 55,000 sharesKRXDART:20260126000297Canonical exit: 19 Apr 2026 (T+90)
- 55,000 sharesShareKRXDART:20260126000301Canonical exit: 26 Apr 2026 (T+90)
- 167,972 sharesKRXDART:20251229000351Canonical exit: 22 Mar 2026 (T+90)
- 1,042 sharesShareKRXDART:20251229000375Canonical exit: 29 Mar 2026 (T+90)
25 of 93 declarations
About SyntekaBio, Inc.
신테카바이오 is a company in the healthcare and pharmaceutical sector, listed on the XKRX market. It focuses on developing innovative solutions for the medical field.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
